When two 4-trifluoromethyl salicylate derivatives [ 2-acetoxy-4-trifluoromethyl-benzoic acid ( triflusal ) and its deacetylated metabolite 2-hydroxy-4-trifluoromethylbenzoic acid ( HTB ) ] were compared with aspirin and sodium salicylate as cyclooxygenase-2 ( COX-2 ) inhibitors , we observed that in bacterial lipopolysaccharide-activated human blood , triflusal , aspirin , and HTB , but not sodium salicylate , inhibited COX-2-mediated prostaglandin E2 ( PGE2 ) production ( IC50 = 0 . 16 , 0 . 18 , 0 . 39 , and >10 mM , respectively ) .
when two 4-trifluoromethyl salicylate derivatives [ 2-acetoxy-4-trifluoromethyl-benzoic acid ( triflusal ) and its deacetylated metabolite 2-hydroxy-4-trifluoromethylbenzoic acid ( htb ) ] were compared with aspirin and sodium salicylate as cyclooxygenase-2 ( cox-2 ) inhibitors , we observed that in bacterial lipopolysaccharide-activated human blood , triflusal , aspirin , and htb , but not sodium salicylate , inhibited cox-2-mediated prostaglandin e2 ( pge2 ) production ( ic50 = 0 . 16 , 0 . 18 , 0 . 39 , and >10 mm , respectively ) .
O O B-other_organic_compound I-other_organic_compound I-other_organic_compound O B-other_organic_compound I-other_organic_compound O B-other_organic_compound O O O B-other_organic_compound I-other_organic_compound B-other_organic_compound I-other_organic_compound O B-other_organic_compound O O O O O O O O O O B-protein_molecule O O O O O O O O O B-tissue I-tissue I-tissue I-tissue O B-other_organic_compound O B-other_organic_compound O O B-other_organic_compound O O O B-other_organic_compound I-other_organic_compound O O B-other_organic_compound I-other_organic_compound I-other_organic_compound O B-other_organic_compound O O O O O O O O O O O O O O O O O O O O O O O O